CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Roche Holding AG Akt 1.04% CHF232.83B ...

Dyne Therapeutics Inc.-5.60% $1.56B ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from ...

Moderna’s head of development, therapeutics, and oncology. “We believe an individualised neoantigen therapy can be this catalyst for innovation and drive us forward towards the next frontier ...

It's unclear how he will impact biotech stocks. Evaluate the expected performance of Moderna (MRNA) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom ...

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...

A social media post claims that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic. After fact checking, we found that the claim is false. According to an Instagram post, “Moderna ...